StreetInsider.com News Articles

Form DEFA14A ADIAL PHARMACEUTICALS,

Fri, 16 Oct 2026 17:16:00 -0400

si-local-file:///var/storage/secattach/20261016/27198695.html

Form 8-K ADIAL PHARMACEUTICALS, For: Oct 15

Fri, 16 Oct 2026 17:15:00 -0400

si-local-file:///var/storage/secattach/20261016/27198686.html

Adial Pharmaceuticals names former Dermavant CSO as chief scientist

Fri, 16 Oct 2026 07:01:49 -0400

Adial Pharmaceuticals, Inc. (Nasdaq: ADIL) has appointed David Rubenstein, M.D., Ph.D., as chief scientist, the company announced Oct. 16, 2026, according to a press release.

Dr. Rubenstein previously served as chief scientific officer at Dermavant Sciences, where he led the development of tapinarof (VTAMA cream 1%), the first AhR agonist approved by the U.S. Food and Drug Administration, for plaque psoriasis and atopic dermatitis. He has also held senior preclinical development roles at Stiefel and GSK, and holds an M.D. and Ph.D. from Duke University.

In his new role, Dr. Rubenstein will oversee discovery, translational, and nonclinical research at Adial, including IND-enabling

Adial Pharmaceuticals names former Dermavant CSO as chief scientist

Fri, 16 Oct 2026 07:01:49 -0400

Adial Pharmaceuticals, Inc. (Nasdaq: ADIL) has appointed David Rubenstein, M.D., Ph.D., as chief scientist, the company announced Oct. 16, 2026, according to a press release.

In his new role, Dr. Rubenstein will oversee discovery, translational, and nonclinical research at Adial, including IND-enabling

Adial Pharmaceuticals Appoints David Rubenstein, M.D., Ph.D., as Chief Scientist to Advance its Colon-Targeted AhR Agonist, AT177, for Ulcerative Colitis

Fri, 16 Oct 2026 07:00:00 -0400

Former Dermavant Chief Scientific Officer led development of tapinarof, the first FDA-approved AhR agonist, from mechanistic understanding through approval and commercialization

Will lead AT177 through IND-enabling studies toward first-in-human trials expected in 2027

GLEN ALLEN, Va., Oct. 16, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (Nasdaq: ADIL) ("Adial" or the "Company"), which recently acquired Azora Therapeutics, today announced the appointment of David Rubenstein, M.D., Ph.D. as Chief Scientist. Dr. Rubenstein will lead the Company's research and scientific strategy, including the continued development of AT177, a proprietary, oral, colon-targeted aryl hydrocarbon receptor (AhR) agonist being

Adial Pharmaceuticals Appoints David Rubenstein, M.D., Ph.D., as Chief Scientist to Advance its Colon-Targeted AhR Agonist, AT177, for Ulcerative Colitis

Fri, 16 Oct 2026 07:00:00 -0400

Former Dermavant Chief Scientific Officer led development of tapinarof, the first FDA-approved AhR agonist, from mechanistic understanding through approval and commercialization

Will lead AT177 through IND-enabling studies toward first-in-human trials expected in 2027

Form DEFA14A ADIAL PHARMACEUTICALS,

Mon, 05 Oct 2026 06:01:00 -0400

si-local-file:///var/storage/secattach/20261005/27145047.html

Form 8-K ADIAL PHARMACEUTICALS, For: Oct 01

Fri, 02 Oct 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20261002/27142467.html

Adial Pharmaceuticals Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Wed, 30 Sep 2026 17:46:00 -0400

GLEN ALLEN, Va., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (Nasdaq: ADIL) (“Adial” or the “Company”) today announced that the Company’s Compensation Committee has granted a new employee stock option to purchase 155,446 shares of common stock as an inducement to such person becoming an employee of the Company.

The option award has an exercise price of $4.22 per share, the closing price of the Company’s common stock on September 25, 2026, the effective date of grant and has a ten-year term. The option award will vest over four years, with 25% vesting

Adial Pharmaceuticals Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Wed, 30 Sep 2026 17:46:00 -0400

Form 4 ADIAL PHARMACEUTICALS, For: Sep 17 Filed by: Young Wendy B.

Mon, 21 Sep 2026 19:25:00 -0400

si-local-file:///var/storage/secattach/20260921/27086358.html

Form DEFA14A ADIAL PHARMACEUTICALS,

Fri, 18 Sep 2026 17:18:00 -0400

si-local-file:///var/storage/secattach/20260918/27081309.html

Form 8-K ADIAL PHARMACEUTICALS, For: Sep 17

Fri, 18 Sep 2026 16:27:00 -0400

si-local-file:///var/storage/secattach/20260918/27080830.html

Form DEFA14A ADIAL PHARMACEUTICALS,

Wed, 16 Sep 2026 17:29:00 -0400

si-local-file:///var/storage/secattach/20260916/27071246.html

Form 8-K ADIAL PHARMACEUTICALS, For: Sep 16

Wed, 16 Sep 2026 17:08:00 -0400

si-local-file:///var/storage/secattach/20260916/27071115.html

Form S-3 ADIAL PHARMACEUTICALS,

Fri, 28 Aug 2026 16:49:00 -0400

si-local-file:///var/storage/secattach/20260828/26998769.html

Form S-3 ADIAL PHARMACEUTICALS,

Fri, 28 Aug 2026 16:49:00 -0400

si-local-file:///var/storage/secattach/20260828/26998769.html

Form S-8 ADIAL PHARMACEUTICALS,

Fri, 28 Aug 2026 16:47:00 -0400

si-local-file:///var/storage/secattach/20260828/26998754.html

Form S-8 ADIAL PHARMACEUTICALS,

Fri, 28 Aug 2026 16:47:00 -0400

si-local-file:///var/storage/secattach/20260828/26998754.html

Form 8-K ADIAL PHARMACEUTICALS, For: Aug 19

Tue, 25 Aug 2026 16:33:00 -0400

si-local-file:///var/storage/secattach/20260825/26975214.html

Form 8-K ADIAL PHARMACEUTICALS, For: Aug 19

Tue, 25 Aug 2026 16:33:00 -0400

si-local-file:///var/storage/secattach/20260825/26975214.html

Adial Pharmaceuticals Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Tue, 25 Aug 2026 16:05:00 -0400

GLEN ALLEN, Va., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (Nasdaq: ADIL) (“Adial” or the “Company”) today announced that the Company’s Compensation Committee has granted a new employee stock option to purchase 307,814 shares of common stock as an inducement to such person becoming an employee of the Company.

The option award has an exercise price of $5.76 per share, the closing price of the Company’s common stock on August 19, 2026, the effective date of grant and has a ten-year term. The option award will vest over four years, with 25% vesting

Adial Pharmaceuticals Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Tue, 25 Aug 2026 16:05:00 -0400

Adial Pharmaceuticals Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Tue, 25 Aug 2026 16:05:00 -0400

Adial Pharmaceuticals Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Tue, 25 Aug 2026 16:05:00 -0400